

Microsoft Bing

国内版 国际版

Sodium glucose cotransporter 2 (SGLT2) inhibitors -New horizon of

Sign in

ALL IMAGES VIDEOS

35 Results Any time

[Full text] Empagliflozin in Type 2 Diabetes Mellitus ...

<https://www.dovepress.com/empagliflozin-in-type-2...>

Cited by: 1 Author: Peng Men, Tianbi Liu, Suodi Zhai

Publish Year: 2020

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are able to lower blood glucose hemoglobin A1c (HbA1c) through increasing urinary glucose excretion by lowering the renal threshold for glucose. 12-1...

Frontiers | Cost-Effectiveness of Canagliflozin Versus ...

<https://www.frontiersin.org/articles/10.3389/fphar.2019.00480>

Cited by: 4 Author: Xingyun Hou, Xu Wan, Bin Wu




Publish Year: 2019

By stimulating glucose excretion in the urine, the sodium glucose co-transporter 2 (SGLT2) inhibitors have been approved as the most recent class of therapies for managing T2DM (Li et al., 2017).

See more

国内版国际版

Microsoft Bing

Sodium glucose cotransporter 2 inhibitors -New horizon of the he:   

ALLIMAGESVIDEOS


11 ResultsAny time ▾

[Covosa-GI-Exam 2 Flashcards | Quizlet](https://quizlet.com/72499842/covosa-gi-exam-2-flash-cards)
<https://quizlet.com/72499842/covosa-gi-exam-2-flash-cards> ▾

Secretion in Stomach-Products. 1. A proteolytic enzyme, pepsin, is secreted as an inactive precursor, pepsinogen. 2. The gastric juice also contains a lipolytic enzyme, lipase, for digestion of triglycerides. 3. Gastric juice contains 45 kDa protein synthesized by parietal cells, called intrinsic factor.

[EXECUTIVE SUMMARY - Canagliflozin \(Invokana\) for Type 2 ...](https://www.ncbi.nlm.nih.gov/books/NBK349588)
<https://www.ncbi.nlm.nih.gov/books/NBK349588>

Background. Canagliflozin (Invokana) is the first antihyperglycemic drug of the sodium-glucose cotransporter-2 (SGLT2) inhibitor class indicated for use in Canada. This CADTH Common Drug Review (CDR) report will focus on the following indication: In combination with metformin and either a sulfonylurea or pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control ...

 See more

国内版

国际版

Sodium glucose cotransporter 2 inhibitors -New horizon of the he



ALL

IMAGES

VIDEOS

11 Results

Any time ▾

[Covosa-GI-Exam 2 Flashcards | Quizlet](#)

<https://quizlet.com/72499842/covosa-gi-exam-2-flash-cards> ▾

Secretion in Stomach-Products. 1. A proteolytic enzyme, pepsin, is secreted as an **inactive** precursor, pepsinogen. 2. The gastric juice also contains a lipolytic enzyme, lipase, for digestion of triglycerides. 3. Gastric juice contains 45 kDa protein synthesized by parietal cells, called intrinsic factor.

[EXECUTIVE SUMMARY - Canagliflozin \(Invokana\) for Type 2 ...](#)

<https://www.ncbi.nlm.nih.gov/books/NBK349588>

Background. Canagliflozin (Invokana) is the first antihyperglycemic drug of the **sodium-glucose cotransporter-2 (SGLT2)** inhibitor class indicated for use in Canada. This CADTH Common Drug Review (CDR) report will focus on the following indication: In combination with metformin and either a sulfonylurea or pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control ...

[Frontiers | Cost-Effectiveness of Canagliflozin Versus ...](#)

<https://www.frontiersin.org/articles/10.3389/fphar.2019.00480> ▾

By stimulating glucose excretion in the urine, the **sodium glucose co-transporter 2 (SGLT2)** inhibitors have been approved as the most recent class of **therapies** for managing T2DM (Li et al., 2017).

Cited by: 6

Author: Xingyun Hou, Xu Wan, Bin Wu

Publish Year: 2019

[Clinical inertia among patients with type 2 diabetes ...](#)

<https://www.sciencedirect.com/science/article/pii/S0168822718309653#>

Dec 01, 2018 · **Failure** to intensify treatment of patients with type 2 diabetes (T2D) in a timely manner is a common challenge. If newer oral anti-diabetic drugs (NOA...

[Obstructive Sleep Apnea: Its Relevance in the Care of ...](#)

<https://clinical.diabetesjournals.org/content/20/3/126> ▾

Jul 01, 2002 · In Brief Obstructive **sleep apnea** (OSA) is a common and frequently unrecognized disorder. It is often found in patients with obesity, diabetes, and cardiovascular disease, and there is growing evidence that **sleep apnea** is independently associated with increased cardiovascular morbidity. This article reviews the presentation, diagnosis, and treatment of OSA and its related health risks.

Cited by: 12

Author: Suzanne Boyer, Vishesh Kapur

Publish Year: 2002

Estimated Reading Time: 11 mins